Subchronic centrifugal mechanical assist in an unheparinized calf model.
The purpose of this study was to determine whether the major centrifugal pumps currently in use in the United States (Medtronic, BioMedicus BioPump and Carmeda-coated BioPump, Sarns 3M centrifugal pump, and St. Jude Medical Lifestream) could function as left mechanical assist devices in the subchronic (72 h) unheparinized calf model. Calves were instrumented for left atrial to aorta ex vivo assist, and the pump flow was set at 3.5 +/- 0.4 L/min. Two calves (Sarns 3M and St. Jude) survived 72 h of pumping without clinical complications. The other 2 calves died at 62 and 66 h (Medtronic BioPump and Carmeda-coated BioPump, respectively); both had pelvic limb paralysis. The seal of the Sarns 3M pump head ruptured after approximately 36 h of pumping and required replacement. On postmortem examination, pump-associated thromboembolic lesions were detected in 3 of the 4 calves in one or more of the following organs: kidneys, pancreas, abomasum, duodenum, ileum, spleen, and lumbar spinal cord. The calf with the Sarns 3M pump had no discernable lesions. Because of the clinical abnormalities and postmortem lesions in the unheparinized calf model, it was suggested that anticoagulation is necessary for conducting centrifugal mechanical assist studies in calves using presently available technology.
Wagner-Mann
C
C
School of Medicine, Department of Veterinary Medicine, University of Missouri, Columbia, USA.
Curtis
J
J
Mann
F A
FA
Turk
J
J
Demmy
T
T
Turpin
T
T
D000704:Analysis of Variance; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D002417:Cattle; D002498:Centrifugation; D006353:Heart-Assist Devices / Q000009:adverse effects / Q000592:standards*; D011183:Postoperative Complications; D015203:Reproducibility of Results; D012770:Shock, Cardiogenic / Q000517:prevention & control; D013923:Thromboembolism / Q000503:physiopathology / Q000517:prevention & control*
D000925:Anticoagulants